OLD National Bancorp IN Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

OLD National Bancorp IN trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 218 shares of the biopharmaceutical company’s stock after selling 60 shares during the period. OLD National Bancorp IN’s holdings in Regeneron Pharmaceuticals were worth $229,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of REGN. Gateway Investment Advisers LLC grew its stake in Regeneron Pharmaceuticals by 13.7% during the first quarter. Gateway Investment Advisers LLC now owns 1,337 shares of the biopharmaceutical company’s stock valued at $1,287,000 after acquiring an additional 161 shares in the last quarter. Wealthcare Advisory Partners LLC grew its stake in Regeneron Pharmaceuticals by 14.4% during the first quarter. Wealthcare Advisory Partners LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $283,000 after acquiring an additional 37 shares in the last quarter. Janiczek Wealth Management LLC lifted its position in Regeneron Pharmaceuticals by 20.1% during the first quarter. Janiczek Wealth Management LLC now owns 221 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 37 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Regeneron Pharmaceuticals by 11.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 23,151 shares of the biopharmaceutical company’s stock valued at $22,283,000 after purchasing an additional 2,412 shares during the last quarter. Finally, 180 Wealth Advisors LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at $218,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 2.2 %

Shares of REGN opened at $941.39 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,211.20. The company has a 50-day moving average of $1,098.29 and a 200 day moving average of $1,040.67. The firm has a market capitalization of $103.73 billion, a price-to-earnings ratio of 27.81, a PEG ratio of 3.40 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the firm posted $8.79 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of several research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $1,260.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Piper Sandler increased their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. Barclays lowered their price objective on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating for the company in a research report on Wednesday. TD Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,102.19.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.